On the basis of the aforementioned information, we conducted a cascade of in vitro and in vivo assays based on the miR-365/TLR4/IRF3/YAP/CDX2 axis to identify novel biomarkers involved in GC tumor progression in order to improve the prognosis and further understand the exact molecular mechanism of GC. This evidence concerns the gene IRF3 and gastric cancer.